Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep111 | Adrenal and Cardiovascular Endocrinology | ECE2022

The “RESCUE” Trial: 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing’s Syndrome

Czerwiec Frank , Drajesk Jeffrey , Hooper Sarah , Hunsicker Kimberly , Jacks Robert , MacPherson Jamie , Marmon Tonya , Katz David

Background: HSD-1, an intracellular enzyme, converts cortisone to cortisol in tissues where cortisol excess is associated with morbidity including liver, adipose, bone, brain, muscle, skin, and eye. SPI-62 is a potent and specific HSD-1 inhibitor in development for treatment of CushingÂ’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In Phase 1 clinical trials SPI-62 was generally well tolerated and associa...

ea0081ep112 | Adrenal and Cardiovascular Endocrinology | ECE2022

The ACSPIRE trial: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition for autonomous cortisol secretion and adrenal cushing’s syndrome

Czerwiec Frank , Drajesk Jeffrey , Hooper Sarah , Hunsicker Kimberly , Jacks Robert , MacPherson Jamie , Marmon Tonya , Katz David

Background: HSD-1, an intracellular enzyme, converts cortisone to cortisol in tissues where cortisol excess is associated with morbidity including liver, adipose, bone, brain, muscle, skin, and eye. SPI-62 is a potent and specific HSD-1 inhibitor in development for treatment of autonomous cortisol secretion (ACS) and CushingÂ’s syndrome, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In Phase 1 clinical trials SPI-62 was generally well tolerated and a...